Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

HC Wainwright & Co. Maintains Buy on Celldex Therapeutics, Raises Price Target to $73

HC Wainwright & Co. analyst Joseph Hafling maintains Celldex Therapeutics (NASDAQ:CLDX) with a Buy and raises the price target from $60 to $73.
byBenzinga Newsdesk
July 1, 2022
1 minute read
Total
0
Shares
0
0
0
0
0
0

HC Wainwright & Co. analyst Joseph Hafling maintains Celldex Therapeutics (NASDAQ:CLDX) with a Buy and raises the price target from $60 to $73.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts